Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.40 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092485 | 1.00 | CYP2A6 (0.64) | CYP2A6FFAR1GPR84IMPDH2HTR2A | |
| SCHEMBL15672105 | 0.85 | CYP2A6 (0.54) | CYP2A6FFAR1GPR84IMPDH2HTR2A | |
| SCHEMBL15331057 | 0.85 | CYP2A6 (0.55) | CYP2A6FFAR1GPR84IMPDH2HTR2A | |
| SCHEMBL29952428 | 0.82 | CYP2A6 (0.70) | CYP2A6IMPDH2ERN1PIM1PIM3 | |
| SCHEMBL29408411 | 0.79 | CYP2A6 (0.66) | CYP2A6IMPDH2PIM1PIM3PIM2 | |
| SCHEMBL248842 | 0.79 | CYP2A6 (0.66) | CYP2A6IMPDH2PIM1PIM3PIM2 | |
| SCHEMBL31447990 | 0.78 | TDO2 (0.52) | CYP2A6FFAR1GPR84HTR2AHTR2C | |
| SCHEMBL16713913 | 0.78 | TDO2 (0.52) | CYP2A6FFAR1GPR84HTR2AHTR2C | |
| SCHEMBL16713915 | 0.78 | TDO2 (0.52) | CYP2A6FFAR1GPR84HTR2AHTR2C | |
| SCHEMBL644301 | 0.78 | CYP2A6 (1.00) | CYP2A6IMPDH2PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| WO-2025060786-A1 | SIX-MEMBERED AND FIVE-MEMBERED FUSED RING DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湘北威尔曼制药股份有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| EP-4313985-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE | Equinorm Ltd (FI) | 2024-02-07 | — | — | EP | disclosed |
| US-11891387-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-06 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220372030-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-24 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022207979-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD (FI) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP2A6 747/4885FFAR1 54/4885GPR84 162/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP2A6 627/4885FFAR1 38/4885GPR84 297/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | CYP2A6 555/4885FFAR1 27/4885GPR84 266/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP2A6 747/4885FFAR1 54/4885GPR84 162/4885 |
| US-11891387-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP2A6 627/4885FFAR1 38/4885GPR84 297/4885 |
| US-20220372030-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP2A6 627/4885FFAR1 38/4885GPR84 297/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CYP2A6 747/4885FFAR1 54/4885GPR84 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.